Trump Is Promising to Decrease Drug Costs. Don’t Depend on It

The Trump administration pledged this week to considerably cut back the excessive costs Individuals generally pay for his or her prescribed drugs. It’s a promise that can undoubtedly come up quick.

On Tuesday, President Donald Trump signed an govt order laying out the steps that the federal authorities, through the Division of Well being and Human Providers, is planning to take to decrease drug costs. Whereas among the proposals are sound, others are unlikely to maneuver the needle. Trump and GOP lawmakers are additionally making ready to, or have already got, enacted different measures that would very effectively increase drug costs for a lot of Individuals.

A significant plank of the chief order includes enhancing the Medicare Drug Pricing Negotiation Program: a Biden-era program that permits the federal government to immediately negotiate the costs that Medicare can pay for among the costliest prescribed drugs in the marketplace. The primary spherical of negotiations occurred final 12 months and resulted in ten medication being discounted, although the worth cuts gained’t come into impact till 2026. The second spherical of negotiations includes 15 medication and can conclude this 12 months, with reductions arriving in 2028.

One of the essential medication on this second spherical is semaglutide, the lively ingredient within the kind 2 diabetes medication Ozempic and Rybelsus, in addition to the weight problems medicine Wegovy. Semaglutide-based medication value upwards of $1,000 per 30 days with out insurance coverage, and plenty of eligible sufferers can’t entry them as a result of excessive listing costs and lack of protection. So if drug costs are actually minimize, it will signify a real accomplishment. However once more, any such low cost wouldn’t arrive till 2028, in Trump’s (hopefully) final 12 months of the presidency. Within the meantime, his HHS has really made it tougher for folks on Medicare to afford these medicines.

At the moment, Medicare can’t immediately cowl any weight reduction medicines, although it will probably present protection to folks taking Ozempic and related medication for diabetes or sure obesity-related situations, comparable to coronary heart illness. The Biden administration proposed a rule final 12 months that may have ended this restriction and opened up protection to some 7 million Individuals on Medicare and Medicaid by 2026. Earlier this month, nevertheless, the Trump administration dropped this proposal. HHS chief Robert F. Kennedy stated final week that the administration is contemplating some type of “framework” to broaden protection, although RFK Jr. himself has repeatedly questioned the worth of those medication previously.

One other wrinkle in Trump’s plan to decrease drug costs issues the so-called “tablet penalty.” Medication are usually not eligible for the negotiation program till they’ve been in the marketplace for a sure period of time. For small molecule prescribed drugs, usually taken as tablets, this delay is at present seven years (really 9 years earlier than the worth minimize comes into impact). However for biologics—extra complicated, expensive-to-produce medication usually taken by injection—the delay is 11 years (13 years actually). Within the govt order, Trump pledged to “align the therapy” of those two drug varieties in this system.

However as David Dayen on the Prospect and others have famous, the chief order doesn’t really say that HHS will shorten the delay of biologics eligible for this system. And present pharma-backed GOP payments attempting to handle this discrepancy have finished so by extending the exclusivity interval of small molecule medication to match that of biologics (options from the Democrats have tried to decrease the interval for each).

In accordance with a KFF evaluation launched on Wednesday, a four-year delay would have eliminated greater than half of the medication included within the negotiation program to this point, together with semaglutide. Going ahead, an extended exclusivity interval for these medication would value the federal government loads of potential financial savings and finally harm the wallets of many Individuals who depend on them.

In a press release Wednesday, Senator Ron Wyden (D-Oregon), a member of the Senate Finance Committee, argued that Trump’s govt order is for certain to solely weaken drug pricing reform.

“Similar to his first time period, Trump is all bark and no chew in terms of decreasing the price of prescribed drugs,” Wyden mentioned. “This govt order is rife with goodies that Huge Pharma has been begging for, primarily by weakening Medicare negotiation, which goes to imply larger costs for American seniors and households whereas the drug firms get a windfall to the tune of $10 billion.”

There are some nuggets of excellent concepts nestled within the govt order, comparable to additional decreasing the price of insulin, attempting to make it simpler for states to import medication (an initiative that began through the first Trump time period), or accelerating the approval of generic medication. However even these proposals are undermined by actions the White Home has taken elsewhere.

The FDA has shed almost 20% of its workforce as a part of a DOGE-orchestrated “restructuring,” for example, which is already hampering its ability to course of potential drug approvals. And the administration has begun to lay the groundwork wanted to impose tariffs on medication imported into the U.S, which might result in larger prices and drug shortages, notably for generic drugs.

Nothing about Trump’s previous or current observe report means that prescribed drugs in America are about to get considerably cheaper. And if we’re actually unfortunate, some medication might turn into much more costly quickly sufficient.